glp-1 drugs eli lilly launches pill, kicking off showdown with Novo Nordisk Eli Lilly's New $299 Month-Long

Recent guidelines for non-alcoholic fatty liver disease (NAFLD)/ fatty liver disease (FLD): are they already outdated and in need of supplementation

10.1016/j.jad.2012.01.013 [DOI] [PubMed] [Google Scholar] Zheng P., Zeng B., Zhou C., Liu M., Fang Z., Xu X., et al

Perhaps Novo Nordisks most novel offering is a once-monthly ultrasound treatment for obesity, currently in early stages of exploration as part of a collaboration with GE Healthcare

Szpunar for her help in creating Table 2 and A

[DOI] [PubMed] [Google Scholar] 26.Dai C., Hang Y., Shostak A., Poffenberger G., Hart N., Prasad N., Phillips N., Levy S.E., Greiner D.L., Shultz L.D., et al

Critical Appraisal of CVOTs and Evidence Gaps While the collective evidence from the CVOTs outlined in Table 1 is compelling, a critical appraisal reveals important heterogeneity and outstanding questions that are crucial for clinical interpretation [62]